JAMA Psychiatry:情感障碍症状积累增加患者死亡风险

2020-04-13 MedSci原创 MedSci原创

情感障碍症状的终生累积可能与死亡率增加有关,解释途径取决于症状的持续时间和程度

近日研究人员考察了情感障碍的终生积累时间与死亡率的关系,并确定潜在的影响因素。
 
研究数据来自MRC国家健康与发展调查,该研究基于社会分层和人口样本,1946年3月英格兰、威尔士和苏格兰的5362个独生子女参与。参与者接受24次随访,最近一次是在2014-2015年。在13-15岁、36岁、43岁以及53岁对参与者情感障碍情况进行评估。研究的主要终点为死亡率。
 
3001名参与者,其中1509名女性(50.3%),1492名男性(49.7%),235名个体(7.8%)在15年的随访中死亡。在性别调整后,经历过1、2和3到4次症状性情感障碍的患者,其早亡率分别比从未经历患者高76%、87%和134%。仅青少年(13-15岁)时期出现症状导致死亡风险增加94%。那些有3到4次病例症状患者,其健康状况较差(32.1%)、普遍使用抗焦虑药(28.4%)、肺功能较差(24.6%)、体力活动较少(23.9%)、吸烟(24.6%)、使用抗抑郁药(20.1%)、饮食异常(16.4%)、脉搏率异常(12.7%)和社会交往存在障碍(11.2%)。
 
研究认为,情感障碍症状的终生累积可能与死亡率增加有关,解释途径取决于症状的持续时间和程度。
 
原始出处:
 
Gemma Archer et al. Association Between Lifetime Affective Symptoms and Premature Mortality. JAMA Psychiatry. April 8, 2020.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 1489e4e7m33暂无昵称

    拿积分

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1983659, encodeId=b329198365954, content=<a href='/topic/show?id=628553048e3' target=_blank style='color:#2F92EE;'>#患者死亡#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53048, encryptionId=628553048e3, topicName=患者死亡)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Oct 11 21:11:39 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1792166, encodeId=1b3d1e92166ca, content=<a href='/topic/show?id=696a14818df' target=_blank style='color:#2F92EE;'>#Psychiatry#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14818, encryptionId=696a14818df, topicName=Psychiatry)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c192448, createdName=diushouji, createdTime=Tue Dec 22 06:11:39 CST 2020, time=2020-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1255965, encodeId=0eb11255965fc, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568731, encodeId=986f1568e31f4, content=<a href='/topic/show?id=8b7d53129cc' target=_blank style='color:#2F92EE;'>#情感障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53129, encryptionId=8b7d53129cc, topicName=情感障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=afcb15435989, createdName=天堂的云, createdTime=Wed Apr 15 10:11:39 CST 2020, time=2020-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=381672, encodeId=dbbe3816e201, content=拿积分, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2020/05/12/c342d58f35f7cda5722de560807a1eb8.jpg, createdBy=a37a5317256, createdName=1489e4e7m33暂无昵称, createdTime=Mon Apr 13 23:38:44 CST 2020, time=2020-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036028, encodeId=83cb103602802, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Mon Apr 13 22:11:39 CST 2020, time=2020-04-13, status=1, ipAttribution=)]
    2020-04-13 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

J Thromb Haemost:抗抑郁药与硬膜下血肿风险

由此可见,抗抑郁药的使用与较高的SDH风险相关,似乎主要限于治疗的第一年。绝对而言,由于SDH发生率较低,因此该风险被认为很小。除了一个可能的例外(三联使用抗抑郁药、NSAID和VKA),将抗抑郁药与抗血栓形成药或NSAID联合使用的SDH风险估计几乎没有相互作用的证据。

Diabetes Care:抗抑郁药与2型糖尿病风险之间的关联

由此可见,长期服用抗抑郁药会以时间和剂量依赖性方式增加2型糖尿病风险。停用抗抑郁药或在糖尿病患者降低剂量可改善其葡萄糖耐量。

恒瑞重磅抗抑郁药获批临床 研发投入超千万

5月14日,恒瑞医药发布公告称,恒瑞医药及子公司上海恒瑞医药有限公司近日收到国家药监局核准签发的关于盐酸(R)-氯胺酮鼻喷剂的《临床试验通知书》,并将于近期开展临床试验。

Neurology:抗抑郁药的5-羟色胺再摄取抑制程度与缺血性卒中风险

由此可见,该基于人群的大型研究表明,强5-羟色胺再摄取抑制的抗抑郁药可能与缺血性卒中发生率的小幅下降有关。

我国抗抑郁药物市场发展现状分析

根据世界卫生组织报告,目前抑郁症是全球第四大疾病负担,也是导致患者功能残疾的主要原因之一,全球抑郁症发病率约为11%,全球约有3.4亿抑郁症患者,大约有1/7的人会在人生的某个阶段遭受抑郁症困扰。

JCEM:抗抑郁药降低了糖尿病患者的死亡风险

由此可见,大多数ATD,而不是RIMA,与DM合并抑郁症患者的死亡率显著降低有关。